Back to search
FDAFDA · Food and drugs·Recall number D-1445-2014

Orphenadrine Citrate Extended Release Tablets, 100 mg a)100-count bottle, (NDC 0185-0022-01) b) 1000-count bottle, (NDC 0185-0022-10), Rx only, Manufactured by Sandoz Inc., Princeton, NJ 08540.

Published July 30, 2014 · Recall initiated: July 11, 2014

Summary

FDA records drug Class III recall D-1445-2014, published July 30, 2014 and initiated July 11, 2014. Recalling firm: Sandoz Inc; Status: Terminated; Reported quantity: 781,000 extended release tablets; Lot: Lot # DM1316; Exp. 05/16 Lot # DM1318; Exp. 05/16. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: Product found to be out of specification (OOS) during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if ORPHENADRINE CITRATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ORPHENADRINE CITRATE
Manufacturer
Sandoz Inc
Distributor
Nationwide
Lot
Lot # DM1316; Exp. 05/16 Lot # DM1318; Exp. 05/16
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Orphenadrine Citrate Extended Release Tablets, 100 mg a)100-count bottle, (NDC 0185-0022-01) b) 1000-count bottle, (NDC 0185-0022-10), Rx only, Manufactured by Sandoz Inc., Princeton, NJ 08540. recalled?

Yes. FDA published recall D-1445-2014 on July 30, 2014. Reported hazard: Failed Dissolution Specifications: Product found to be out of specification (OOS) during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ORPHENADRINE CITRATE.